Polyethylene Glycol
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Polyethylene Glycol: Congenital ichthyosiform erythroderma
One-Sentence Summary
Polyethylene glycol is an osmotic agent and lubricating/hydrating agent, originally used for constipation and dry eye (xerophthalmia). The TxGNN model predicts it may be effective for congenital ichthyosiform erythroderma, but there are currently no clinical trials and no publications supporting this direction. The prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Congenital ichthyosiform erythroderma |
| TxGNN Prediction Score | 0.9903 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 4 of 4) |
| Number of DINs | 4 (marketed: 4) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, polyethylene glycol is an osmotic agent and a hydrating/lubricating excipient. Its use in constipation and dry eye is established, and mechanistically it might be applicable to skin conditions marked by dryness and scaling.
A speculative link is that topical barrier or hydration effects could ease the scaling and dryness (xerosis) seen in ichthyosis. However, congenital ichthyosiform erythroderma is a genetic keratinization disorder (for example, TGM1 or ALOX12B variants). Neither the osmotic nor the lubricant properties address the underlying pathology.
The prediction therefore remains a hypothesis. The high score (0.9903) is the only support, and no study data back it.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02354551 | RHINARIS NASAL MIST | Not specified | Not specified |
| 00551805 | SECARIS | Not specified | Not specified |
| 02352699 | RHINARIS NASAL GEL | Not specified | Not specified |
| 00777838 | PEGLYTE POWDER | Not specified | Not specified |
All four licences are valid products. Two are nasal products (RHINARIS), and PEGLYTE is a powder. None is a topical skin product.
Safety Considerations
No label-based warnings, contraindications or drug interaction data were available for this report. Please refer to the package insert for safety information.
The drug-disease knowledge graph does list conditions associated with contraindication for polyethylene glycol. These are not drawn from label text and should be verified against the product monograph. Main groups include:
- Gastrointestinal obstruction and motility: ileus, paralytic ileus, intestinal obstruction, toxic megacolon, pyloric stenosis, familial visceral myopathy, appendicitis
- Cardiovascular and renal: hypertension, congestive heart failure, cardiovascular/heart disease, kidney disease, anuria, pyoureter, nephrocalcinosis
- Metabolic and endocrine: diabetes mellitus, hyperglycemia, diabetic ketoacidosis, hypercalcemia, potassium deficiency, phosphorus metabolism disease, hyperthyroidism, Graves disease, thyrotoxicosis
- Neurological: epilepsy
- Eye: angle-closure glaucoma, eye infectious disease, conjunctivitis
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score, with no clinical trials or literature (Evidence Level L5). The proposed mechanism does not address the genetic basis of the disease, and the available Canadian products are not topical skin formulations.
To proceed, the following is needed:
- Package insert warnings and contraindications from Health Canada (a blocking gap for safety screening)
- Mechanism of action data for polyethylene glycol
- A literature and trial search for polyethylene glycol in ichthyosis and related keratinization disorders
- Assessment of route and formulation compatibility (a topical product would likely be needed)
- Preclinical or mechanistic evidence that hydration or barrier effects offer meaningful benefit in this genetic condition
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.